Co-Diagnostics, Inc. files an 8-K: Material Modifications to Rights of Security Holders
Co-Diagnostics filed an 8-K reporting material modifications to the rights of security holders, an amendment to its articles or bylaws, and a change in fiscal year. The filing's details are not in the headline, so the specific impact on shareholders is unclear from this item alone.
From the filing
Item 3.03: Material Modifications to Rights of Security Holders; Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; Item 7.01: Regulation FD Disclosure; Item 9.01: Financial Statements and Exhibits
Items listed in the filing. The full text is at SEC EDGAR.
Who is reporting it
- GlobeNewswirefirst at Nov 19, 2026, 9:09 AM ESTRead at GlobeNewswire (opens in a new tab)
- SEC EDGARfirst at Nov 19, 2026, 9:18 AM ESTRead at SEC EDGAR (opens in a new tab)
- Seeking Alphafirst at Nov 19, 2026, 10:27 AM ESTRead at Seeking Alpha (opens in a new tab)
Story so far
Reported by 3 sources
Lisata Therapeutics announced a one-for-fifteen reverse stock split of its common stock, with split-adjusted Nasdaq trading under the LSTA symbol starting at the November 23, 2026 open and a new CUSIP.
- Nov 19, 2026, 9:09 AM EST · GlobeNewswireConfirmedLisata Therapeutics, Inc. Announces Reverse Stock Split Effective November 23, 2026
- Nov 19, 2026, 9:18 AM EST · SEC EDGARConfirmedLisata Therapeutics, Inc. files an 8-K: Material Modifications to Rights of Security Holders
- Nov 19, 2026, 10:27 AM EST · Seeking AlphaConfirmedLisata Therapeutics announces one-for-fifteen reverse stock split
- Nov 19, 2026, 5:10 PM EST · SEC EDGAR · this storyConfirmedCo-Diagnostics, Inc. files an 8-K: Material Modifications to Rights of Security Holders
Comments
Log in or create a free account to comment.
No comments yet.
The headline links to the original source; the summary is written by The Market Standard. Nothing here is financial advice.